Targeting the cancer microenvironment

The recognition of bacterial infections or foreign substances is mediated and controlled by the human immune system. This innate and adaptive immune system comprises the most important metabolic and cellulare processes to fight against infections and other diseases. Paradoxically, this immune system is also involved in the development of systemic diseases and cancer. Therefore it is of utmost importance to further understand fundamental biochemical processes involved in the cellular reactions of the immune system which can lead directly to novel therapies against systemic diseases and cancer.

The enormeous complexity of the immune system comprises different cell types. Two types, M1- and M2-type macrophages are involved in inflammatory defense mechanisms (M1) but also healing processes (M2). These M2-type macrophages are also known to associate with cancer cells and supporting their growth (Tumor-associated macrophages, TAM´s). The mechanism by which these cell types can differentiate into each other is called the polarization process.

M2 polarization can be targeted by a novel biochemical checkpoint

In a new study published in Cell Reports the research teams of the system biologist and biochemist Wolfram Weckwerth and the immunologist Thomas Weichhart have found a novel biochemical switch involved in the polarization and proliferation of M2 macrophages. This biochemical checkpoint branches from the glycolytic pathway - the major pathway in human metabolism for glucose breakdown - to provide molecular units for rapid cell proliferation and differentiation. If this pathway is inhibited by specific substances the M2 polarization and proliferation is downregulated. This has direct consequences for the understanding of TAM's and the treatment of cancer. „Our hypothesis is that if we inhibit the growth of M2-type macrophages in the microenvironment of cancer cells we could revoke the supportive effect for cancer growth. This biochemical checkpoint which we found in these M2-type macrophages is exactly the point for targeting their growth inhibition," says Wolfram Weckwerth.

The two labs of Thomas Weichhart and Wolfram Weckwerth are now intensively working to study this mechanism in more detail and to develop potential strategies for cancer cell treatment. Central for this project is the Vienna Metabolomics Center which enables the thorough study of these complex metabolic processes of the human immune system and cancer metabolism by combining metabolite profiling and data-driven computational modelling. The Vienna Metabolomics Center was also recently involved in a study for cancer treatment by specific combinations of fasting and drug administration leading to reduced tumor growth.

Jayne Louise Wilson, Thomas Nägele, Monika Linke, Florian Deme, Stephanie D Fritsch, Hannah Katharina Mayr, Zhengnan Cai, Karl Katholnig, Xiaoliang Sun, Lena Fragner, Anne Miller, Arvand Haschemi, Alexandra Popa, Andreas Bergthaler, Markus Hengstschläger, Thomas Weichhart, Wolfram Weckwerth.
Inverse Data-Driven Modeling and MultiomicsAnalysis Reveals Phgdh as a Metabolic Checkpointof Macrophage Polarization and Proliferation.
Cell Reports 30, 1542–1552, February 4, 2020. doi: 10.1016/j.celrep.2020.01.011.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...